The study, called EPITOPE, led by senior author A. Wesley Burks, MD, CEO of UNC Health and dean of the UNC School of Medicine, and contributing author Edwin Kim, MD, MS, associate professor of pediatrics in the Division of Pediatric Allergy and Immunology at the UNC School of Medicine, shows superior results in desensitizing children to peanuts. Results were recently published in the New England Journal of Medicine.
Peanut allergy affects approximately two percent of children in the United States, Canada, and other westernized countries, with a rapidly rising prevalence over the past 20 years. Currently there are no FDA approved treatment options for peanut-allergic children under the age of 4 years, but further research into the safety, efficacy, and tolerability of epicutaneous immunotherapy (EPIT) could play a significant role in novel options for immunotherapy. The EPITOPE trial, led by senior author A. Wesley Burks, MD, CEO of UNC Health and dean of the UNC School of Medicine, evaluating the safety profile of Viaskin, a novel form of EPIT, among peanut-allergic toddlers shows that after 12 months of treatment in children aged 1-3 years, the treatment was found to be statistically superior to placebo in desensitizing participants to peanuts, increasing the peanut dose triggering allergic symptoms. Edwin Kim, MD, MS, associate professor of pediatrics in the Division of Pediatric Allergy and Immunology at the UNC School of Medicine is also a contributing author to the paper.
These are very encouraging results and move us closer to a treatment option for this increasingly prevalent and serious allergic condition, said Burks. We hope this will be available to patients in the not too distant future.
With feeding guidelines now recommending the introduction of peanut in the first year of life, we are diagnosing peanut allergy earlier and earlier, said Kim. The EPITOPE trial shows that the Viaskin peanut patch may not only be an effective treatment option but importantly a simple and safe option in this very young age group.
Published in the New England Journal of Medicine, results showed that more than one-third (37-percent) of Viaskin Peanut-treated participants in the EPITOPE trial, sponsored by DBV Technologies, a clinical-stage biopharmaceutical company, reached a cumulative reactive dose 3444 mg. Viaskin, a patch-based non-oral immunotherapy, is a potential new class of treatment that harnesses the immune properties of the skin. It has the potential to help modify individuals underlying food allergy by desensitizing the immune system to an allergen.Viaskin Peanut is currently under clinical investigation and is not yet approved by the U.S. Food and Drug Administration or any other regulatory agencies. If approved, Viaskin Peanut would provide an additional treatment option to offer patients and families for whom the standard of care aloneallergen avoidance and use of rescue medicationmay not be enough.
EPITOPE was a Phase 3, randomized, double-blind, placebo-controlled trial designed to allow participants to go about their normal daily activities without restrictions. After one year of treatment, Viaskin Peanut resulted in statistically superior desensitization compared with placebo, with treatment responder rates of 67.0% and 33.5%, respectively. Additionally, a shift towards less severe food challenge reactions was seen following 12 months of treatment. Similar to previous studies of Viaskin Peanut in children, the most common adverse events (AEs) were local application site reactions, which decreased in frequency and severity over time. Low rates of treatment-related anaphylaxis and epinephrine use were observed. This study demonstrated that 12 months of daily EPIT with a patch containing 250 g peanut protein (1/1000th of one peanut) was sufficient to decrease the likelihood of experiencing an allergic reaction following accidental peanut exposure. Viaskin Peanut was well-tolerated by a majority of participants and had low discontinuations due to AEs and high compliance rates.
UNC School of Medicine contact: Brittany Phillips
See the rest here:
12 Months of Treatment with EPIT Superior to Placebo in ... - UNC Health and UNC School of Medicine
- Fellow Focus in Four: Marat Kribis, MD, Rheumatology, Allergy and Immunology - Yale School of Medicine - April 15th, 2024 [April 15th, 2024]
- Long COVID Can Now Be Detected in the Blood - Technology Networks - April 15th, 2024 [April 15th, 2024]
- Rimjhim Agarwal selected as Major Symposium speaker at the American Association of Immunologists ... - La Jolla Institute for Immunology - March 29th, 2024 [March 29th, 2024]
- Seeking new horizons: Where innovators find opportunities in a fast-changing immunology landscape - IQVIA - March 29th, 2024 [March 29th, 2024]
- Researchers identify new way to inhibit immune cells that drive allergic asthma - EurekAlert - March 29th, 2024 [March 29th, 2024]
- Innovation in Oncology and Cancer Immunology Research - Boehringer Ingelheim - March 29th, 2024 [March 29th, 2024]
- Measles outbreaks show the risk of under-vaccination | News | Harvard T.H. Chan School of Public Health - HSPH News - March 29th, 2024 [March 29th, 2024]
- Immunology-oncology ELISA Kits Market to Witness a Healthy Growth by 2030 - WhaTech - March 29th, 2024 [March 29th, 2024]
- Spring Allergy Season Is Getting Worse. Here's What to Know. - The New York Times - March 29th, 2024 [March 29th, 2024]
- Multiple sclerosis has distinct subtypes, study finds, pointing to different treatments - STAT - March 29th, 2024 [March 29th, 2024]
- Researchers identify viable vaccine targets for hepatitis C infections - News-Medical.Net - March 29th, 2024 [March 29th, 2024]
- Three research projects awarded funding from the Immunology Institute Pilot Project program - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE - Scrip - February 29th, 2024 [February 29th, 2024]
- AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... - PR Newswire - February 29th, 2024 [February 29th, 2024]
- Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system - Nature.com - February 29th, 2024 [February 29th, 2024]
- Renowned immunologist and four-decade UAB researcher Max Cooper, M.D., will deliver this year's Marx Lecture - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Inactivation of TGF- signaling in CAR-T cells | Cellular & Molecular Immunology - Nature.com - February 29th, 2024 [February 29th, 2024]
- Babies use their immune system differently but efficiently | Cornell Chronicle - Cornell Chronicle - February 29th, 2024 [February 29th, 2024]
- Antibody reduces allergic reactions to multiple foods in NIH clinical trial - National Institutes of Health (NIH) (.gov) - February 29th, 2024 [February 29th, 2024]
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Theratechnologies announces publication in Frontiers in Immunology on TH1902 - TipRanks.com - TipRanks - February 21st, 2024 [February 21st, 2024]
- Smoking has long-term effects on the immune system - Institut Pasteur - February 21st, 2024 [February 21st, 2024]
- Spring Allergies Attack More Than Just Your Nose - ACAAI Public Website - American College of Allergy Asthma and Immunology - February 21st, 2024 [February 21st, 2024]
- Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Shikhar Mehrotra named co-leader of Cancer Biology and Immunology research program at MUSC Hollings - The Cancer Letter - January 27th, 2024 [January 27th, 2024]
- Gut Microbiome Benefits of Breast Milk Revealed in Mouse Study - Technology Networks - January 27th, 2024 [January 27th, 2024]
- Research on Immunological Diseases Launches with Hungarian Participation - Hungary Today - January 27th, 2024 [January 27th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Associated Press - January 8th, 2024 [January 8th, 2024]
- TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration - Business Wire - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former Westside Pavilion into centers for research on immunology and quantum science - KABC-TV - January 8th, 2024 [January 8th, 2024]
- HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases - PR Newswire - January 8th, 2024 [January 8th, 2024]
- Beyond Cytotoxicity: The Importance of T Cell Memory - The Scientist - January 8th, 2024 [January 8th, 2024]
- IKAROS: Unlocking the secrets of the immune system's key player - News-Medical.Net - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Caledonian-Record - January 8th, 2024 [January 8th, 2024]
- Revolutionizing Vaccine Research: The Power of a New Algorithm - SciTechDaily - December 31st, 2023 [December 31st, 2023]
- Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people ... - Nature.com - December 22nd, 2023 [December 22nd, 2023]
- Two new practice parameters offer recommendations for treating anaphylaxis and atopic dermatitis - News-Medical.Net - December 22nd, 2023 [December 22nd, 2023]
- Physician and Patient (Un)Wellness in Allergy and Immunology During COVID-19 and Beyond: Lessons for the Future - Physician's Weekly - December 22nd, 2023 [December 22nd, 2023]
- Researchers Identify Why Some Cancers Do Not Respond to Immunotherapy - NYU Langone Health - December 22nd, 2023 [December 22nd, 2023]
- MU's Haval Shirwan recognized for achievements in immunology - Columbia Daily Tribune - December 22nd, 2023 [December 22nd, 2023]
- Parker Institute for Cancer Immunotherapy (PICI) Welcomes Weill Cornell Medicine to Cancer Research Consortium - Weill Cornell Medicine Newsroom - December 14th, 2023 [December 14th, 2023]
- Annals of Allergy, Asthma and Immunology Examines Effects of Climate Change on Allergic Conditions - Newswise - December 14th, 2023 [December 14th, 2023]
- British Society for Immunology response to the NHS vaccination strategy - British Society for Immunology | - December 14th, 2023 [December 14th, 2023]
- NYU Langone Health in the NewsFriday, December 8, 2023 - NYU Langone Health - December 14th, 2023 [December 14th, 2023]
- Arturo Casadevall Named Distinguished Fellow by the American Association of Immunologists - Johns Hopkins Bloomberg School of Public Health - December 14th, 2023 [December 14th, 2023]
- ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scien - PharmiWeb.com - December 14th, 2023 [December 14th, 2023]
- Ishares Genomics Immunology And Healthcare Etf ($IDNA) Proactive Strategies - Stock Traders Daily - December 14th, 2023 [December 14th, 2023]
- Medical Breakthroughs Fueling Infection Prevention Market: Immunology and Modern Medicine Advancements to ... - PR Newswire - December 14th, 2023 [December 14th, 2023]
- Cancer therapy bexmarilimab awakens immune cells to attack tumors that have avoided the detection of the immune ... - EurekAlert - December 14th, 2023 [December 14th, 2023]
- Testing Cancer Immunotherapies on Mice with Human Immune Systems - Mirage News - December 14th, 2023 [December 14th, 2023]
- Georgetown School of Medicine's Department of Immunology Hosts Talk About Therapeutic Vaccine for Autoimmune ... - Georgetown University The Hoya - December 6th, 2023 [December 6th, 2023]
- Long COVID Research Is a Bit of a Mess - Technology Networks - December 6th, 2023 [December 6th, 2023]
- Research Assistant/Research Associate in Immunology job with ... - Times Higher Education - May 13th, 2023 [May 13th, 2023]
- Pioneering learning resource helps academic win top teaching award - Swansea University - May 13th, 2023 [May 13th, 2023]
- Director of Discover Biology, Neuroscience & Immunology- full-time ... - Merck KGaA - May 13th, 2023 [May 13th, 2023]
- Absci, The Kennedy Institute for immunotherapies development - Pharmaceutical Technology - May 13th, 2023 [May 13th, 2023]
- Customizing T Cell-Based Immunotherapies in a 'SNAP' - UPMC - May 13th, 2023 [May 13th, 2023]
- Understanding Lupus: an interview with the Garvan Institute - News-Medical.Net - May 13th, 2023 [May 13th, 2023]
- Professor Laura Mackay wins LEO Foundation Award in Region ... - The Peter Doherty Institute for Infection and Immunity - May 13th, 2023 [May 13th, 2023]
- Trinity's Prof Ed Lavelle recognised by ISI for vaccine research - SiliconRepublic.com - May 13th, 2023 [May 13th, 2023]
- Allison Institute announces appointment of inaugural members - EurekAlert - May 13th, 2023 [May 13th, 2023]
- Study sheds light on how the immune system protects the body - EurekAlert - May 13th, 2023 [May 13th, 2023]
- Werewolf Therapeutics Reports First Quarter 2023 Financial Results ... - BioSpace - May 13th, 2023 [May 13th, 2023]
- PeaceHealth cuts Bellingham jobs, announces clinic closure and reduces some services - Yahoo News - May 13th, 2023 [May 13th, 2023]
- Help! My skin is itchy - Parkview Health - May 13th, 2023 [May 13th, 2023]
- Takeda reports 12.8% rise in FY2022 revenue - Pharmaceutical Technology - May 13th, 2023 [May 13th, 2023]
- Welcoming a new column: Vasso's corner - The immune system - Neos Kosmos - May 13th, 2023 [May 13th, 2023]
- UC statement on Gov. Newsom's 2023-24 revised budget proposal - University of California - May 13th, 2023 [May 13th, 2023]
- Jasper Therapeutics (JSPR) Appoints Stephen J. Galli to its Board - StreetInsider.com - May 13th, 2023 [May 13th, 2023]
- DICE Therapeutics Reports First Quarter 2023 Financial Results and ... - InvestorsObserver - May 13th, 2023 [May 13th, 2023]
- Cannabis-derived products have flooded US market Two ... - Down To Earth Magazine - May 13th, 2023 [May 13th, 2023]
- NYU Langone Health in the NewsFriday, May 12, 2023 - NYU Langone Health - May 13th, 2023 [May 13th, 2023]
- UNION therapeutics to present at 4th Annual Dermatology Drug ... - InvestorsObserver - May 13th, 2023 [May 13th, 2023]
- Russell Investments Decreases Stake in Argenx SE by 20% in Q4 ... - Best Stocks - May 13th, 2023 [May 13th, 2023]
- How my training helps me to address health disparities in multiple ... - Nature.com - May 13th, 2023 [May 13th, 2023]
- Positive trial results for RSV infant treatment: Sanofi - Medical Xpress - May 13th, 2023 [May 13th, 2023]
- How Can You Find Out If You're Allergic to a Medication Before You ... - Verywell Health - May 13th, 2023 [May 13th, 2023]
- HUTCHMED Announces Appointment of Independent Non ... - GlobeNewswire - May 13th, 2023 [May 13th, 2023]
- The Wistar Institute, Pennsylvania Biotechnology Center and Baruch S. Blumberg Institute Forge Strategic Collaboration to Support Regional Biotech... - May 13th, 2023 [May 13th, 2023]
- Humanized Mouse and Rat Model Market worth $338 million | MarketsandMarkets - Yahoo Finance - May 13th, 2023 [May 13th, 2023]